跳至主要内容
临床试验/NCT00201461
NCT00201461
Unknown
2 期

A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the STARFlex® Septal Closure System Versus Best Medical Therapy in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale

NMT Medical1 个研究点 分布在 1 个国家目标入组 900 人2003年6月

概览

阶段
2 期
干预措施
Best medical therapy
疾病 / 适应症
Patent Foramen Ovale
发起方
NMT Medical
入组人数
900
试验地点
1
主要终点
Two (2) year incidence of stroke or Hard TIA
最后更新
17年前

概览

简要总结

The primary objective of the study is to determine whether the STARFlex® septal closure system will safely and effectively prevent a recurrent embolic stroke/transient ischemic attack (TIA) and mortality in patients with a PFO and to demonstrate superiority of the STARFlex® device compared to best medical therapy.

注册库
clinicaltrials.gov
开始日期
2003年6月
结束日期
2010年4月
最后更新
17年前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

发起方
NMT Medical

入排标准

入选标准

  • Age 18-60 years inclusive.
  • Positive contrast valsalva bubble study by trans-esophageal echocardiogram (TEE) for patent foramen ovale (PFO), with or without atrial septal aneurysm.
  • Stroke or clinically definite TIA (contact study coordinator).
  • Be able to comply with follow up over two years.
  • Be competent to, or have a legal guardian competent to, provide informed consent following full disclosure of risks and benefits of both treatment arms by a study investigator.
  • Venous access capable of accepting a 10F minimum vascular sheath.
  • Have, or be willing to, discontinue hormonal based contraceptive use prior to enrollment and for the term of the study.
  • Has cardiac anatomy based on enrollment echocardiogram that will allow for placement of the implant if randomized to the implant arm.
  • Note: Additional inclusion criteria may apply. Contact study coordinator or principal investigator for details.
  • Post-randomization - device patients only

排除标准

  • Carotid artery stenosis \> 50%.
  • Intracranial stenosis \> 50% appropriate to symptoms.
  • Complex aortic arch atheroma with high risk features for embolism
  • Aortic arch, carotid or vertebral artery dissection.
  • Mitral or aortic valve stenosis, vegetation, or calcification \> 5 mm mitral annular calcification (MAC) thickness.
  • Active pregnancy.
  • Active infections (contact study coordinator).
  • Active infective endocarditis or bacteremia.
  • Prosthetic heart valves in any location.
  • Anterior MI within 3 months of neurological event.

研究组 & 干预措施

1

Best medical therapy

干预措施: Best medical therapy

2

STARFlex arm

干预措施: STARFlex septal closure system

结局指标

主要结局

Two (2) year incidence of stroke or Hard TIA

时间窗: 2 years

All cause mortality for the first 30 days of follow up/discharge, whichever is longer

时间窗: 30 days

Neurological mortality from 31 days of follow up (F/U) or longer

时间窗: 31 days

次要结局

  • Incidence of primary endpoint as a total and broken down by event type/treatment group in: stroke/TIA patients (pts) and DW-MR+ pts with symptoms < 24 hours(< 24 hrs)
  • Incidence of primary endpoint in BMT group(2 years)
  • Per treatment group, incidence of relevant/notable adverse events (AEs)(2 years)
  • Device group: (1) Incidence of primary endpoint in pts prescribed aspirin (325 versus 81 mg) daily, (2) Incidence of relevant/notable AEs(2 years)

研究点 (1)

Loading locations...

相似试验